Menu
Real-world data showed that patients with metastatic breast cancer receiving palbociclib had a numerically higher rate of neutropenia than patients receiving ribociclib.
In this real-world retrospective study, more patients in the ribociclib cohort compared with palbociclib and abemaciclib maintained starting doses and fewer patients decreased to 50% of the starting dose.
In addition to the significant benefit observed in the MONARCH 2 study across first- and second-line treatment, marked effects were observed in patients with less encouraging prognostic indicators.
Adding palbociclib to fulvestrant as first-line therapy improves 1-year progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative, endocrine-sensitive, advanced breast cancer.
Across the MONALEESA-2, -3, and -7 clinical trials, first-line treatment with endocrine therapy and ribociclib mitigated negative effects on quality of life, global health scores, pain, and emotional functioning.
While progression-free survival was similar, overall survival was better in CDK4/6 inhibitor combinations as first-line therapy followed by everolimus combinations and chemotherapy.
In a range of groups with PIK3CA alterations, recent findings demonstrate a clear and consistent clinical benefit of alpelisib when combined with fulvestrant, which was detected in circulating tumor DNA by next-generation sequencing.
For patients with hormone receptor–positive, HER2-negative metastatic breast cancer, response rates for platinum-based chemotherapy were lower than historically observed in patients with triple-negative breast cancer, associated with poor outcomes.
The majority of patients with metastatic breast cancer receiving treatment with CDK4/6 inhibitors had progression-free survival, behaving similarly when used as first-line therapy or after adjuvant hormonal therapy.
Page 1 of 4
Results 1 - 10 of 32

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Thank You to Our Corporate Sponsors and Alliance Partners!

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Industry Relations Council Member

    Industry Relations
    Council Member

  • Industry Relations Council Member

    Industry Relations
    Council Member

  • National Alliance Partner

    National Alliance Partner

  • Health System Partner

    Health System Partner

  • Health System Partner

    Health System Partner

  • Health System Partner

    Health System Partner

  • Industry Relations Alliance Partner

    Industry Relations Alliance Partner

  • Industry Relations Alliance Partner

    Industry Relations Alliance Partner